Publications by authors named "Hartmut Kirchner"

Claim this Profile
T
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
Anna Both, Jürgen Krauter, Frederik Damm, Felicitas Thol, Gudrun Göhring, Hartmut Kirchner

Ann Hematol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.
Felicitas Thol, Claudia Winschel, Ann-Kathrin Sonntag, Frederik Damm, Katharina Wagner, Hartmut Kirchner

Ann Hematol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-2 upregulates CD86 expression on human CD4(+) and CD8(+) T cells.
Ananta Paine, Hartmut Kirchner, Stephan Immenschuh, Mathias Oelke, Rainer Blasczyk

J Immunol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Felicitas Thol, Frederik Damm, Andrea Lüdeking, Claudia Winschel, Katharina Wagner, Hartmut Kirchner

J Clin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Andreas Engert, Annette Plütschow, Hans Theodor Eich, Andreas Lohri, Bernd Dörken, Hartmut Kirchner

N Engl J Med· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Felicitas Thol, Frederik Damm, Katharina Wagner, Gudrun Göhring, Brigitte Schlegelberger, Hartmut Kirchner

Blood· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.
Thomas Steiner, Hartmut Kirchner, Michael Siebels, Christian Doehn, Hans Heynemann

J Cancer Res Clin Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Katharina Wagner, Frederik Damm, Gudrun Göhring, Kerstin Görlich, Michael Heuser, Hartmut H Kirchner

J Clin Oncol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.
Hartmut Kirchner, Dirk Strumberg, Amit Bahl, Friedrich Overkamp

Expert Rev Anticancer Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Frederik Damm, Michael Heuser, Michael Morgan, Haiyang Yun, Anika Grosshennig, Hartmut Kirchner

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.
Marie von Lilienfeld-Toal, Corinna Hahn-Ast, Hartmut Kirchner, Dimitri Flieger, Gottfried Dölken

Haematologica· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Rüdiger Hehlmann, Ute Berger, Markus Pfirrmann, Hermann Heimpel, Andreas Hochhaus, Hartmut H Kirchner

Blood· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
Ulrike Anneliese Nitz, Svjetlana Mohrmann, Johannes Fischer, Walter Lindemann, Wolfgang E Berdel, Hartmut Kirchner

Lancet· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technique and results of hyperthermic (41 degrees C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis.
Carsten Schröder, Stefan Fisher, Anne Christin Pieck, Axel Müller, Ulrich Jaehde, Hartmut Kirchner

Eur J Cardiothorac Surg· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Norbert Schmitz, Beate Pfistner, Michael Sextro, Markus Sieber, Angelo M Carella, Hartmut Kirchner

Lancet· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Markus Sieber, Hans Tesch, Beate Pfistner, Ulrich Rueffer, Bernd Lathan, Hartmut Kirchner

J Clin Oncol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis